Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Urology Reports
Published in: Current Urology Reports 11/2023

01-11-2023 | Urinary Tract Infection

The Potential Role of Persister Cells in Urinary Tract Infections

Authors: Butool Durrani, Ashu Mohammad, Bernardita M. Ljubetic, Amy D. Dobberfuhl

Published in: Current Urology Reports | Issue 11/2023

Login to get access

Abstract

Purpose of Review

This review explores the role of persister cells in urinary tract infections (UTIs). UTIs are one of the most common bacterial infections, affecting millions of people worldwide. Persister cells are a subpopulation of bacteria with dormant metabolic activity which allows survival in the presence of antibiotics.

Recent Findings

This review summarizes recent research on the pathogenesis of persister cell formation in UTIs, the impact of persister cells on the effectiveness of antibiotics, the challenges they pose for treatment, and the need for new strategies to target these cells. Furthermore, this review examines the current state of research on the identification and characterization of persister cells in UTIs, as well as the future directions for investigations in this field.

Summary

This review highlights the importance of understanding the role of persister cells in UTIs and the potential impact of targeting these cells in the development of new treatments.
Literature
1.
Patel HB, Soni ST, Bhagyalaxmi A, Patel NM. Causative agents of urinary tract infections and their antimicrobial susceptibility patterns at a referral center in Western India: an audit to help clinicians prevent antibiotic misuse. J Family Med Prim Care. 2019;8:154–9.PubMedPubMedCentralCrossRef
2.
Yang X, Chen H, Zheng Y, Qu S, Wang H, Yi F. Disease burden and long-term trends of urinary tract infections: a worldwide report. Front Public Health. 2022;10.
3.
Geerlings SE. Clinical presentations and epidemiology of urinary tract infections. Microbiol Spectr. 2016;4:4.5.03.
4.
Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13:269–84.PubMedPubMedCentralCrossRef
5.
Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269–284.
6.
Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28:1–13.PubMedCrossRef
7.
Blango MG, Ott EM, Erman A, Veranic P, Mulvey MA. Forced resurgence and targeting of intracellular uropathogenic Escherichia coli reservoirs. PLoS ONE. 2014;9:e93327.PubMedPubMedCentralCrossRef
8.
Mysorekar IU, Hultgren SJ. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci U S A. 2006;103:14170–5.PubMedPubMedCentralCrossRef
9.
Fisher RA, Gollan B, Helaine S. Persistent bacterial infections and persister cells. Nat Rev Microbiol. 2017;15:453–64.PubMedCrossRef
10.
11.
Krishna A, Tesfalem Z, Sabyasachy M, Omnia I, Heather S, Leonard V. S, James L. W Evaluation of a sequential antibiotic treatment regimen of ampicillin, ciprofloxacin and fosfomycin against Escherichia coli CFT073 in the hollow fiber infection model compared with simultaneous combination treatment. 26 November 2022.
12.
Niu H, Cui P, Shi W, Zhang S, Feng J, Wang Y, Sullivan D, Zhang W, Zhu B, Zhang Y. Identification of anti-persister activity against uropathogenic Escherichia coli from a clinical drug library. Antibiotics (Basel). 2015;4:179–87.PubMedCrossRef
13.
Mulcahy LR, Burns JL, Lory S, Lewis K. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol. 2010;192:6191–9.PubMedPubMedCentralCrossRef
14.
Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett. 2004;230:13–8.PubMedCrossRef
15.
Mulvey MA, Schilling JD, Martinez JJ,, Hultgren SJ. Bad bugs and beleaguered bladders: interplay between uropathogenic Escherichia coli and innate host defenses. Proc Natl Acad Sci U S A. 2000.
16.
Conlon BP, Rowe SE, Gandt AB, Nuxoll AS, Donegan NP, Zalis EA, Clair G, Adkins JN, Cheung AL, Lewis K. Persister formation in Staphylococcus aureus is associated with ATP depletion. Nat Microbiol. 2016;1:16051.PubMedPubMedCentralCrossRef
17.
18.
• Bahmaninejad P, Ghafourian S, Mahmoudi M, Maleki A, Sadeghifard N, Badakhsh B. Persister cells as a possible cause of antibiotic therapy failure in Helicobacter pylori. JGH Open. 2021;5:493–7. Demonstrates role of persister cells in recurrence of infection and antibiotic treatment failure.PubMedPubMedCentralCrossRef
19.
20.
Luidalepp H, Jõers A, Kaldalu N, Tenson T. Age of inoculum strongly influences persister frequency and can mask effects of mutations implicated in altered persistence. J Bacteriol. 2011;193:3598–605.PubMedPubMedCentralCrossRef
21.
Alteri CJ, Hagan EC, Sivick KE, Smith SN, Mobley HLT. Mucosal immunization with iron receptor antigens protects against urinary tract infection. PLoS Pathog. 2009;5:e1000586.PubMedPubMedCentralCrossRef
22.
23.
24.
Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35:322–32.PubMedCrossRef
25.
Conlon B, Nakayasu E, Fleck L, LaFleur M, Isabella V, Coleman K, Leonard S, Smith R, Adkins J, Lewis K. Killing persister cells and eradicating a biofilm infection by activating the ClpP protease. Nature. 2013;503:365–70.PubMedPubMedCentralCrossRef
26.
• Zou J, Peng B, Qu J, Zheng J. Are bacterial persisters dormant cells only? Front Microbiol. 2022;12: 708580. Suggests the mechanistic basis for bacterial persistence.PubMedPubMedCentralCrossRef
27.
28.
Mulvey MA, Schilling JD, Hultgren SJ. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect Immun. 2001;69:4572–9.PubMedPubMedCentralCrossRef
29.
Pacios O, Blasco L, Bleriot I, et al. (p)ppGpp and its role in bacterial persistence: new challenges. Antimicrob Agents Chemother. 2020;64:e01283–e1320.PubMedPubMedCentralCrossRef
30.
Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. Bacterial persistence as a phenotypic switch. Science. 2004;305:1622–5.PubMedCrossRef
31.
Jahandeh N, Ranjbar R, Behzadi P, Behzadi E. Uropathogenic Escherichia coli virulence genes: invaluable approaches for designing DNA microarray probes. Cent European J Urol. 2015;68:452–8.PubMedPubMedCentral
32.
Liu S, Wu N, Zhang S, Yuan Y, Zhang W, Zhang Y. Variable persister gene interactions with (p)ppGpp for persister formation in Escherichia coli. Front Microbiol. 2017;8.
33.
Wang X, Wood TK. Toxin-antitoxin systems influence biofilm and persister cell formation and the general stress response ▿. Appl Environ Microbiol. 2011;77:5577–83.PubMedPubMedCentralCrossRef
34.
35.
36.
Kulesus RR, Diaz-Perez K, Slechta ES, Eto DS, Mulvey MA. Impact of the RNA chaperone Hfq on the fitness and virulence potential of uropathogenic Escherichia coli. Infect Immun. 2008;76:3019–26.PubMedPubMedCentralCrossRef
37.
Culham DE, Lu A, Jishage M, Krogfelt KA, Ishihama A, Wood JM. The osmotic stress response and virulence in pyelonephritis isolates of Escherichia coli: contributions of RpoS, ProP, ProU and other systems. Microbiology (Reading). 2001;147:1657–70.PubMedCrossRef
38.
Kaldalu N, Hauryliuk V, Turnbull KJ, La Mensa A, Putrinš M, Tenson T. In vitro studies of persister cells. Microbiol Mol Biol Rev. 2020;84:e00070–e120.PubMedPubMedCentralCrossRef
39.
Alam A, Bröms JE, Kumar R, Sjöstedt A. The role of ClpB in bacterial stress responses and virulence. Front Mol Biosci. 2021;8.
40.
Partridge JD, Bodenmiller DM, Humphrys MS, Spiro S. NsrR targets in the Escherichia coli genome: new insights into DNA sequence requirements for binding and a role for NsrR in the regulation of motility. Mol Microbiol. 2009;73:680–94.PubMedCrossRef
41.
Leatham-Jensen MP, Mokszycki ME, Rowley DC, et al. Uropathogenic Escherichia coli metabolite-dependent quiescence and persistence may explain antibiotic tolerance during urinary tract infection. mSphere 2016;1:e00055–15.
42.
Schmidt NW, Deshayes S, Hawker S, Blacker A, Kasko AM, Wong GCL. Engineering persister-specific antibiotics with synergistic antimicrobial functions. ACS Nano. 2014;8:8786–93.PubMedPubMedCentralCrossRef
43.
Conlon BP, Nakayasu ES, Fleck LE, LaFleur MD, Isabella VM, Coleman K, Leonard SN, Smith RD, Adkins JN, Lewis K. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature. 2013;503:365–70.PubMedPubMedCentralCrossRef
44.
Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103–120.PubMedCrossRef
45.
46.
Schumacher MA, Balani P, Min J, Chinnam NB, Hansen S, Vulić M, Lewis K, Brennan RG. HipBA–promoter structures reveal the basis of heritable multidrug tolerance. Nature. 2015;524:59–64.PubMedPubMedCentralCrossRef
47.
Conlon BP. Staphylococcus aureus chronic and relapsing infections: evidence of a role for persister cells: an investigation of persister cells, their formation and their role in S. aureus disease. BioEssays. 2014;36:991–6.PubMedCrossRef
48.
Sampaio NMV, Dunlop MJ. Functional roles of microbial cell-to-cell heterogeneity and emerging technologies for analysis and control. Curr Opin Microbiol. 2020;57:87–94.PubMedPubMedCentralCrossRef
49.
Putrinš M, Kogermann K, Lukk E, Lippus M, Varik V, Tenson T. Phenotypic heterogeneity enables uropathogenic Escherichia coli to evade killing by antibiotics and serum complement. Infect Immun. 2015;83:1056–67.PubMedPubMedCentralCrossRef
50.
Vankadari A, Akshatha K, Anisha S, Poidal Mohammed-ali T, Indrani K, Vijaya KD. Survival and virulence potential of drug-resistant E. coli in simulated gut conditions and antibiotic challenge. Int J Environ Res Public Health. 2022;19.
51.
• Sulaiman JE, Lam H. Proteomic study of the survival and resuscitation mechanisms of filamentous persisters in an evolved Escherichia coli population from cyclic ampicillin treatment. mSystems. 2020;5:e00462–20. This study shows from a system-level perspective, proteomics is the most suitable tool to study persisters cells.
52.
Conlon BP, Rowe SE, Lewis K. Persister cells in biofilm associated infections. In: Donelli G, editor. Biofilm-based Healthcare-associated Infections, vol. II. Cham: Springer International Publishing; 2015;1–9.
53.
•• Lopes BS, Hanafiah A, Nachimuthu R, Muthupandian S, Md Nesran ZN, Patil S. The role of antimicrobial peptides as antimicrobial and antibiofilm agents in tackling the silent pandemic of antimicrobial resistance. Molecules. 2022;27:2995. This paper summarises the role of antimicrobial peptides (AMPs) in combating antimicrobial resistance.PubMedPubMedCentralCrossRef
54.
Erdem I, Kara Ali R, Ardic E, Elbasan Omar S, Mutlu R, Topkaya AE. Community-acquired lower urinary tract infections: etiology, antimicrobial resistance, and treatment results in female patients. J Glob Infect Dis. 2018;10:129–32.PubMedPubMedCentralCrossRef
55.
Aziminia N, Hadjipavlou M, Philippou Y, Pandian SS, Malde S, Hammadeh MY. Vaccines for the prevention of recurrent urinary tract infections: a systematic review. BJU Int. 2019 May;123(5):753-768. https://​doi.​org/​10.​1111/​bju.​14606. Epub 2018 Dec 19.
56.
57.
Tacconelli E. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics.
58.
Munoz-Davila MJ. Role of old antibiotics in the era of antibiotic resistance. highlighted nitrofurantoin for the treatment of lower urinary tract infections. Antibiotics (Basel). 2014;3:39–48.PubMedCrossRef
59.
Gágyor I, Bleidorn J, Kochen MM, Schmiemann G, Wegscheider K, Hummers-Pradier E. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ. 2015;351:h6544.PubMedPubMedCentralCrossRef
60.
61.
Gupta K, Grigoryan L, Trautner B. Urinary tract infection. Ann Intern Med. 2017;167:ITC49–ITC64.
62.
Rodriguez-Mañas L. Urinary tract infections in the elderly: a review of disease characteristics and current treatment options. Drugs Context 9:2020–4–13.
63.
64.
Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev 2015:CD008772.
65.
Beerepoot MAJ, Geerlings SE, van Haarst EP, van Charante NM, Ter Riet G,. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. J Urol. 2013;190:1981–9.PubMedCrossRef
66.
Karlsson M, Scherbak N, Khalaf H, Olsson P-E, Jass J. Substances released from probiotic Lactobacillus rhamnosus GR-1 potentiate NF-κB activity in Escherichia coli-stimulated urinary bladder cells. FEMS Immunol Med Microbiol. 2012;66:147–56.PubMedCrossRef
67.
Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014;32:79–84.PubMedCrossRef
68.
69.
Fjell CD, Hiss JA, Hancock REW, Schneider G. Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov. 2012;11:37–51.CrossRef
70.
Tossi A, Sandri L, Giangaspero A. Amphipathic, alpha-helical antimicrobial peptides. Biopolymers. 2000;55:4–30.PubMedCrossRef
71.
Kaye KS, Belley A, Barth P, et al. Effect of cefepime/enmetazobactam vs piperacillin/tazopactam on clinical cure of microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis. JAMA. Published online October 4, 2022. https://​doi.​org/​10.​1001/​jama.​2022.​17034.
72.
73.
Zhong Z-X, Cui Z-H, Li X-J, et al. Nitrofurantoin combined with amikacin: a promising alternative strategy for combating MDR uropathogenic Escherichia coli. Front Cell Infect Microbiol. 2020;10.
74.
Zumla A, Rao M, Wallis RS, et al. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. Lancet Infect Dis. 2016;16:e47–63.PubMedPubMedCentralCrossRef
75.
Schütze S, Kaufmann A, Bunkowski S, Ribes S, Nau R. Interferon-gamma impairs phagocytosis of Escherichia coli by primary murine peritoneal macrophages stimulated with LPS and differentially modulates proinflammatory cytokine release. Cytokine X. 2021;3:100057.PubMedPubMedCentralCrossRef
76.
Ching CB, Gupta S, Li B, Cortado H, Mayne N, Jackson AR, McHugh KM, Becknell B. Interleukin-6/Stat3 signaling has an essential role in the host antimicrobial response to urinary tract infection. Kidney Int. 2018;93:1320–9.PubMedPubMedCentralCrossRef
77.
Orman MA, Brynildsen MP. Inhibition of stationary phase respiration impairs persister formation in E. coli. Nat Commun. 2015;6:7983.
78.
Cirz RT, Chin JK, Andes DR, de Crécy-Lagard V, Craig WA, Romesberg FE. Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol. 2005;3:e176.PubMedPubMedCentralCrossRef
79.
Zarkan A, Matuszewska M, Trigg SB, et al. Inhibition of indole production increases the activity of quinolone antibiotics against E. coli persisters. Sci Rep. 2020;10:11742.
80.
Chegini Z, Khoshbayan A, Vesal S, Moradabadi A, Hashemi A, Shariati A. Bacteriophage therapy for inhibition of multi drug-resistant uropathogenic bacteria: a narrative review. Ann Clin Microbiol Antimicrob. 2021;20:30.PubMedPubMedCentralCrossRef
81.
Sybesma W, Zbinden R, Chanishvili N, Kutateladze M, Chkhotua A, Ujmajuridze A, Mehnert U, Kessler TM. Bacteriophages as potential treatment for urinary tract infections. Front Microbiol. 2016;7:465.PubMedPubMedCentralCrossRef
82.
Yan G, Liu J, Ma Q, et al. The N-terminal and central domain of colicin A enables phage lysin to lyse Escherichia coli extracellularly. Antonie Van Leeuwenhoek. 2017;110:1627–35.PubMedCrossRef
83.
84.
Bhargava K, Nath G, Bhargava A, Aseri GK, Jain N. Phage therapeutics: from promises to practices and prospectives. Appl Microbiol Biotechnol. 2021;105:9047–67.PubMedPubMedCentralCrossRef
85.
•• Gupta S, Kumar P, Rathi B, Verma V, Dhanda RS, Devi P, Yadav M. Targeting of uropathogenic Escherichia coli papG gene using CRISPR-dot nanocomplex reduced virulence of UPEC. Sci Rep. 2021;11:17801. Relevant paper suggesting Cri-dots nanocomplex as a novel anti-bacterial strategy against multi-drug resistant UPEC.PubMedPubMedCentralCrossRef
86.
87.
Gomaa AA, Klumpe HE, Luo ML, Selle K, Barrangou R, Beisel CL. Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems. mBio. 2014;5:e00928–13.
88.
89.
Ingersoll MA, Kline KA, Nielsen HV, Hultgren SJ. G-CSF induction early in uropathogenic Escherichia coli infection of the urinary tract modulates host immunity. Cell Microbiol. 2008;10:2568–78.PubMedPubMedCentralCrossRef
90.
Butler D, Ambite I, Wan MLY, Tran TH, Wullt B, Svanborg C. Immunomodulation therapy offers new molecular strategies to treat UTI. Nat Rev Urol. 2022;19:419–37.PubMedPubMedCentralCrossRef
91.
92.
Aggarwal N, Lotfollahzadeh S. Recurrent urinary tract infections. StatPearls. 2023.
93.
94.
Maslowska KH, Makiela-Dzbenska K, Fijalkowska IJ. The SOS system: a complex and tightly regulated response to DNA damage. Environ Mol Mutagen. 2019;60:368–84.PubMedPubMedCentralCrossRef
95.
Werneburg GT. Catheter-associated urinary tract infections: current challenges and future prospects. Res Rep Urol. 2022;14:109–33.PubMedPubMedCentral
96.
97.
Pardeshi P. Prevalence of urinary tract infections and current scenario of antibiotic susceptibility pattern of bacteria causing UTI. Indian J Microbiol Res. 2018;5:334–8.
Metadata
Title
The Potential Role of Persister Cells in Urinary Tract Infections
Authors
Butool Durrani
Ashu Mohammad
Bernardita M. Ljubetic
Amy D. Dobberfuhl
Publication date
01-11-2023
Publisher
Springer US
Published in
Current Urology Reports / Issue 11/2023
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-023-01182-5

Other articles of this Issue 11/2023

Current Urology Reports 11/2023 Go to the issue

ReviewPaper

Guiding Clinical Decision Making for Surgical Incontinence Treatment After Prostatectomy: A Review of the Literature

ReviewPaper

Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.)

ReviewPaper

The State of Urotrauma Education Among Residency Programs in the United States: A Systematic Review and Meta-Analysis

ReviewPaper

Pathophysiologic Insights into the Transition from Asymptomatic Bacteriuria to Urinary Tract Infection

ReviewPaper

Recent Advances in Surgical Simulation For Resident Education